| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.VACCINE.2014.11.049 |
| P698 | PubMed publication ID | 25482842 |
| P2093 | author name string | Richard I Walker | |
| P2860 | cites work | Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae | Q64449334 |
| Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains | Q64449454 | ||
| Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. | Q64948328 | ||
| Age-Specific Prevalence of Serum Antibodies to the Invasion Plasmid and Lipopolysaccharide Antigens of Shigella Species in Chilean and North American Populations | Q68159705 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| Sublingual immunization induces broad-based systemic and mucosal immune responses in mice | Q81587050 | ||
| Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a | Q84363216 | ||
| Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses | Q84564316 | ||
| Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine | Q84592118 | ||
| Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice | Q84938205 | ||
| Production of glycoprotein vaccines in Escherichia coli | Q24628546 | ||
| Global, regional, and national causes of child mortality in 2008: a systematic analysis | Q28282386 | ||
| High yield production process for Shigella outer membrane particles | Q28728768 | ||
| Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000 | Q29620061 | ||
| Magnitude and impact of diarrheal diseases | Q30309920 | ||
| Recombinant PorA, the Major Outer Membrane Protein ofCampylobacter jejuni, Provides Heterologous Protection in an Adult Mouse Intestinal Colonization Model | Q30432472 | ||
| Malnutrition as an enteric infectious disease with long-term effects on child development | Q30438831 | ||
| Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. | Q30448313 | ||
| Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area | Q30851263 | ||
| Identification of a Campylobacter jejuni protein that cross-reacts with cholera toxin | Q33282235 | ||
| Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants | Q33557800 | ||
| Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli | Q33558374 | ||
| Etiology of diarrhea in older children, adolescents and adults: a systematic review | Q33651068 | ||
| Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin | Q33859430 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin | Q33899693 | ||
| Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model | Q33983350 | ||
| Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro | Q34224319 | ||
| Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study | Q34345075 | ||
| Novel antigens for enterotoxigenic Escherichia coli vaccines | Q34349166 | ||
| Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems | Q34598569 | ||
| Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera | Q34787413 | ||
| Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. | Q35066293 | ||
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier | Q35480510 | ||
| Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit | Q35598035 | ||
| A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phas | Q35598235 | ||
| Broadly protective Shigella vaccine based on type III secretion apparatus proteins | Q35805439 | ||
| Enterotoxigenic Escherichia coli virulence factors and vaccine approaches | Q35918509 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain | Q36431701 | ||
| The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease | Q36505159 | ||
| Live-attenuated Shigella vaccines | Q36689023 | ||
| Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease | Q36708480 | ||
| Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model | Q36872727 | ||
| Progress and pitfalls in Shigella vaccine research | Q37105553 | ||
| Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a | Q37116180 | ||
| Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines | Q37156758 | ||
| Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli | Q37335500 | ||
| Modern vaccines. Enteric infections | Q37584841 | ||
| Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli | Q37623734 | ||
| Inactivated and subunit vaccines to prevent shigellosis | Q37640115 | ||
| Diarrhoea morbidity and mortality in older children, adolescents, and adults | Q37716033 | ||
| Sublingual vaccination | Q37832086 | ||
| Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans | Q38032878 | ||
| Recent progress towards development of a Shigella vaccine | Q38068954 | ||
| Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate | Q38114268 | ||
| Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala | Q38900076 | ||
| Comorbidity in childhood in northern Ghana: magnitude, associated factors, and impact on mortality | Q39002126 | ||
| Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. | Q39146446 | ||
| Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants | Q39433548 | ||
| Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine | Q39517102 | ||
| Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells | Q39610195 | ||
| Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown | Q39614072 | ||
| Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity | Q39821844 | ||
| Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a | Q40255046 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine | Q40897058 | ||
| Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | Q42117985 | ||
| Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. | Q43432983 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein | Q43867706 | ||
| Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium | Q43982547 | ||
| Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease | Q44891342 | ||
| Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model | Q46307485 | ||
| Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine | Q46902186 | ||
| Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine | Q46938617 | ||
| Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. | Q51745561 | ||
| Updating the DALYs for diarrhoeal disease. | Q51957442 | ||
| Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers. | Q52056758 | ||
| Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. | Q52125486 | ||
| Vaccine potential for inactivated shigellae. | Q53581992 | ||
| Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administe | Q54314338 | ||
| Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. | Q54442796 | ||
| Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. | Q55043303 | ||
| Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial | Q57926913 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| enterotoxigenic Escherichia coli | Q265214 | ||
| P304 | page(s) | 954-965 | |
| P577 | publication date | 2014-12-05 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children | |
| P478 | volume | 33 |
| Q37057975 | Antibodies derived from an enterotoxigenic Escherichia coli (ETEC) adhesin tip MEFA (multiepitope fusion antigen) against adherence of nine ETEC adhesins: CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS21 and EtpA. |
| Q64076764 | Antibodies induced by enterotoxigenic Escherichia coli (ETEC) adhesin major structural subunit and minor tip adhesin subunit equivalently inhibit bacteria adherence in vitro |
| Q41172706 | Bacteriophages are the major drivers of Shigella flexneri serotype 1c genome plasticity: a complete genome analysis. |
| Q91193628 | Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial |
| Q92801042 | Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate |
| Q55315300 | Co-administered Tag-Less Toxoid Fusion 3xSTaN12S-mnLTR192G/L211A and CFA/I/II/IV MEFA (Multiepitope Fusion Antigen) Induce Neutralizing Antibodies to 7 Adhesins (CFA/I, CS1-CS6) and Both Enterotoxins (LT, STa) of Enterotoxigenic Escherichia coli (ET |
| Q59138059 | Cross-Protective Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain |
| Q35998767 | Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea |
| Q39361401 | Current pathogenic Escherichia coli foodborne outbreak cases and therapy development |
| Q47880791 | Development of live attenuated bacterial vaccines targeting Escherichia coli heat-labile and heat-stable enterotoxins |
| Q47269501 | Enterotoxigenic Escherichia coli (ETEC) adhesin-toxoid MEFA (multiepitope fusion antigen) CFA/I/II/IV-3xSTaN12S-mnLTG192G/L211A derived antibodies inhibit adherence of seven adhesins (CFA/I, CFA/II & CFA/IV), neutralize enterotoxicity of both toxins |
| Q61810395 | Establishment, validation and application of a New World Primate model of ETEC disease for vaccine development |
| Q40173337 | Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. |
| Q58441156 | Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016 |
| Q64270378 | Genome Analysis of Shigella flexneri Serotype 3b Strain SFL1520 Reveals Significant Horizontal Gene Acquisitions Including a Multidrug Resistance Cassette |
| Q40109217 | Identification of epitope-based peptide vaccine candidates against enterotoxigenic Escherichia coli: a comparative genomics and immunoinformatics approach |
| Q40899096 | Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates. |
| Q55322314 | Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers. |
| Q50652449 | Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine. |
| Q41715897 | MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA. |
| Q46246924 | Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections |
| Q36281365 | Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge |
| Q28546827 | Molecular Characterization of Enterotoxin-Producing Escherichia coli Collected in 2011-2012, Russia |
| Q57927103 | Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016 |
| Q30252432 | Multiplex real time PCR panels to identify fourteen colonization factors of enterotoxigenic Escherichia coli (ETEC) |
| Q47592750 | Neutralizing Anti-Heat-Stable Toxin (STa) Antibodies Derived from Enterotoxigenic Escherichia coli Toxoid Fusions with STa Proteins Containing N12S, L9A/N12S, or N12S/A14T Mutations Show Little Cross-Reactivity with Guanylin or Uroguanylin. |
| Q27011190 | Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens |
| Q39065850 | Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTaN12S-dmLT protect against STa+ enterotoxigenic Escherichia coli (ETEC) diarrhea in a pig model |
| Q47093864 | Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine |
| Q43096821 | Presentation matters: Buffers, packaging, and delivery devices for new, oral enteric vaccines for infants |
| Q41008205 | Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli |
| Q37477196 | Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q88867094 | Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q34518700 | Status of vaccine research and development for enterotoxigenic Escherichia coli |
| Q92261985 | Technical product attributes in development of an oral enteric vaccine for infants |
| Q55432397 | The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. |
| Q38753453 | The genomic signatures of Shigella evolution, adaptation and geographical spread |
Search more.